Purinergic responses of HT-29 cells, a colonic adenocarcinoma cell line, are mediated by P2Y2 and/or P2Y4R. Enhanced expression of A2BR on colorectal cancer cells that are proliferating suggests that antagonists to A2BR may be a promising therapeutic target for colorectal cancer (Ma et al., 2010; Molck et al., 2016). This evidence concerns the gene P2RY2 and colorectal cancer.